BARD1 Life Sciences

Established in WA: 2016
BARD1 Life Sciences is an ASX-listed Swiss-based biotech firm involved in the development and commercialisation of a blood test for the BARD1 protein biomarkers of early stage lung cancer. In December 2015 the Perth-based resources company Eurogold announced that it would acquire BARD1AG in a reverse takeover deal. The deal completed with the relisting of the company on the ASX as BARD1 Life Sciences in June 2016.
Bio last updated 26 Jul 2016

Article Timeline

Access to our data for BARD1 Life Sciences is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

BARD1 Life Sciences is included in 1 list - Public Companies - Industrial.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

To access ,

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
thThe Go2 People0%0%
252ndBARD1 Life Sciences40%-10%
430thRoto-Gro International3%0%
508thRace Oncology-7%0%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


195th↓BARD1 Life Sciences$54k
224th↓Race Oncology$0
225th↓Roto-Gro International$0
228th-The Go2 People$0
239 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from BARD1 Life Sciences

1500thIrmgard Irminger-Finger$5k
1508thPeter Gunzburg$3k
847thBrett Montgomery$1k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer